Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia

Kenneth F. Bradstock, Alec Morley, Karen Byth, Jeff Szer, Ian Prosser, Paul Cannell, Ian Irving, John F. Seymour

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

An intensive induction regimen, consisting of idarubicin and high dose cytarabine, was assessed in 19 adult patients, median age 44 years, with newly diagnosed precursor-B acute lymphoblastic leukemia (ALL). Patients achieving a complete response (CR) were given an attenuated consolidation course. The primary endpoints were induction death rate and incidence of serious non-hematological toxicity. Grades 3-4 diarrhoea occurred in 47% of patients during induction. Two patients (11%) died during induction therapy, and 2 were withdrawn due to resistant disease or prolonged marrow hypoplasia. Fifteen patients achieved CR (79%), but levels of minimal residual disease (MRD) after induction were comparable with those previously observed using a modified pediatric protocol. Overall survival at 5 years was 36.8% while leukemia-free survival was 44.1%. An intensive AML protocol used in adults with ALL resulted in substantial toxicity and provided similar levels of cytoreduction to conventional ALL protocols, without improving long-term outcomes.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalContemporary Clinical Trials Communications
Volume4
DOIs
Publication statusPublished - 15 Dec 2016

Bibliographical note

©2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords

  • Acute lymphoblastic leukemia
  • Adults
  • High dose cytarabine
  • Minimal residual disease

Fingerprint Dive into the research topics of 'Effects of intensive induction and consolidation chemotherapy with idarubicin and high dose cytarabine on minimal residual disease levels in newly diagnosed adult precursor-B acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this